
|Videos|November 17, 2016
- NSCLC (Issue 11)
- Volume 4
- Issue 2
Clinical Trials Exploring Bevacizumab in NSCLC
Author(s)Catherine Shu, MD
Catherine Shu, MD, medical oncologist, Division of Hematology/Oncology, Columbia University Medical Center, discusses two clinical trials exploring the use of bevacizumab (Avastin) in patients with non-small cell lung cancer.
Advertisement
Articles in this issue
about 9 years ago
Erlotinib Plus Bevacizumab in EGFR-Mutant NSCLCabout 9 years ago
Expert Explores Treatments for Biomarker-Negative Lung Cancerabout 9 years ago
Erlotinib/Bevacizumab Combo Warrants Consideration for EGFR+ NSCLCabout 9 years ago
The Significance of Surgery Quality in NSCLCabout 9 years ago
Practice-Changing Translational Advances Predicted for NSCLCabout 9 years ago
Addressing the Challenges of Treating Non-Driver NSCLCAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5

















